Depomed stock forecast

Depomed Inc (DEPO) Stock Soars on Starboard Stake By William White, InvestorPlace Writer Apr 8, 2016 Depomed stock was up on Friday following news that activist hedge fund Starboard Value has

Depomed - Overview | Assertio Therapeutics, Inc. Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1 Expects to Capture Significant Operating and Product Portfolio Synergies Upwards of $40 Million , Accelerating Revenue Growth and Creating Shareholder Value Arthur Higgins to … DEPO Stock Quote of Depomed Inc - InvestorPlace Depomed Inc (DEPO) Stock Soars on Starboard Stake By William White, InvestorPlace Writer Apr 8, 2016 Depomed stock was up on Friday following news that activist hedge fund Starboard Value has ASRT | Assertio Therapeutics Inc. Profile | MarketWatch

Assertio Therapeutics (NasdaqGS:ASRT) - Share price, News ...

ASRT Stock Price | Assertio Therapeutics Inc. Stock Quote ... DepoMed stock price target cut to $51 from $66 at UBS. Aug. 15, 2017 at 9:55 a.m. ET by Tomi Kilgore. DepoMed Q2 rev. $100.4 million vs. expectations $100.1 million. Market Scenario Forecast Assertio Therapeutics, Inc. (ASRT) Stock Price, Quote ... Find the latest Assertio Therapeutics, Inc. (ASRT) stock quote, history, news and other vital information to help you with your stock trading and investing. ASRT - Assertio Therapeutics Inc Stock quote - CNNMoney.com

Find the latest Assertio Therapeutics, Inc. (ASRT) stock quote, history, news and other vital information to help you with your stock trading and investing.

in an All-Stock Transaction, Representing a 42 Percent Premium to Depomed's The acquisition price reflects a premium of 40 percent to Depomed's closing 

Get your free Depomed Inc stock live and up-to-date data - DEPO Quote, charts, rates, analysis, news & forecasts. Enter Now!

Depomed - Overview | Assertio Therapeutics, Inc. Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1 Expects to Capture Significant Operating and Product Portfolio Synergies Upwards of $40 Million , Accelerating Revenue Growth and Creating Shareholder Value Arthur Higgins to …

Assertio Therapeutics - Wikipedia

View the latest ASRT stock quote and chart on MSN Money. Preliminary Solicitation Statement to Include Proposed Nominees for Depomed's Board Trends And Forecast To 2026|Pfizer, Depomed

Assertio Therapeutics (NasdaqGS:ASRT) - Share price, News ... In addition, the company offers long-acting cosyntropin, an alcohol-free formulation of synthetic adrenocorticotropic hormone. Assertio Therapeutics, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc. The company was formerly known as Depomed Inc. and changed its name to Assertio Therapeutics, Inc. in August 2018.